相关实验视频

Updated: May 31, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

抗氧化剂库尔库米诺酸对Aβ1-42粉样的结构性影响

Angelo Santoro¹, Antonio Ricci², Manuela Rodriquez³

¹Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.

Antioxidants (Basel, Switzerland)

|January 25, 2025

概括

这项研究探讨了黄素及其衍生物如何与粉样蛋白-β (Aβ) 相互作用,为预防阿尔茨海默病提供了潜在的策略.

科学领域:

生物化学和分子生物学
神经科学是一个神经科学.
药理学药理学是指药理学的学科.

背景情况:

在溶液中amyloid-beta (Aβ) 的错误折叠与阿尔茨海默氏症 (AD) 病原发生有关.
亚β聚合引发了内质网膜 (ER) 压力,反应性氧物种 (ROS) 和细胞功能障碍.
黄素及其衍生物是已知的抗氧化剂,可以减轻ER压力并影响Aβ二次结构.

研究的目的:

在黄素和六种衍生物的存在下,研究Aβ(1-42) 的构造性行为.
探索这些化合物的潜力,以防止Aβ聚合物的形成,特别是与脂质双层相互作用.
了解库尔库米诺和Aβ之间的相互作用背后的分子机制.

主要方法:

循环二极化 (CD) 光谱法被用来研究Aβ(1-42) 的形状变化.
研究了各种系统中的相互作用,包括涉及脂质双层的系统.
用分子动力学模拟来可视化水系统中的相互作用.

主要成果:

在所有测试系统中,四基库明 (THC) 衍生物与Aβ1-42相互作用.
循环库尔库明 (CYC) 和双甲基库尔库明 (BMDC) 仅在不太稳定的构造中与Aβ1-42相互作用.
分子动力学模拟提供了关于类药物如何调节表面暴露的见解.

结论:

特定的黄素衍生物,特别是THC,在调节Aβ1-42形状方面表现出潜在的潜力.
这些发现表明,通过防止Aβ聚合,阿尔茨海默病的治疗途径是可能的.
这项研究强调了胺类药物影响的-溶剂相互作用在聚合过程中的重要性.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.抗氧化剂抗氧化剂是一种抗氧化剂.一个圆形的二重化.库尔库明是一种黄素.细胞内膜网膜的压力应激分子动力学分子动力学不折叠的蛋白质反应反应

更多相关视频

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

相关概念视频

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...